Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Retained Earnings (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Retained Earnings data on record, last reported at -$460000.0 in Q1 2026.

  • On a quarterly basis, Retained Earnings fell 209.52% to -$460000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$460000.0, a 209.52% decrease, with the full-year FY2025 number at $621000.0, up 100.14% from a year prior.
  • Retained Earnings reached -$460000.0 in Q1 2026 per OLMA's latest filing, down from $621000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for OLMA hit a ceiling of $621000.0 in Q4 2025 and a floor of -$435.1 million in Q4 2024.
  • A 5-year average of -$112.5 million and a median of -$518000.0 in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 1143314.29% in 2022, then skyrocketed 4300.0% in 2025.
  • Tracing OLMA's Retained Earnings over 5 years: stood at -$1.8 million in 2022, then soared by 119.14% to $347000.0 in 2023, then crashed by 125490.78% to -$435.1 million in 2024, then skyrocketed by 100.14% to $621000.0 in 2025, then tumbled by 174.07% to -$460000.0 in 2026.
  • Business Quant data shows Retained Earnings for OLMA at -$460000.0 in Q1 2026, $621000.0 in Q4 2025, and $526000.0 in Q3 2025.